A blood-brain barrier-like vascular gate in small cell lung cancer and other neuroendocrine cancers blocks immune cells and drives resistance to immunotherapy. Targeting the proteins IGF1R or IGFBP5 boosts CD8+ T cell infiltration and enhances anti-PD1 therapy.